Terremoto Biosciences patents AKT1 inhibitors for cancer Feb. 26, 2025 Terremoto Biosciences Inc. has synthesized new 3 H -imidazo[4,5- b ]pyridine compounds acting as RAC-α serine/threonine-protein ...
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival Eligible patients had AKT1 E17K–mutated metastatic tumors that progressed with standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback